Clinical efficacy of Atezolizumab and Bevacizumab in the treatment of initially borderline resectable advanced liver cancer

Conversion therapy has become the core in the treatment of borderline resectable or unresectable liver cancer, which provides resectable opportunities for more advanced liver cancer patients. In accordance with the first‑choice treatment regimen recommended by the guidelines, the authors reported a successful case of Atezolizumab and Bevacizumab (T+A regimen) conversion therapy. The patient with initially borderline resectable advanced liver cancer was performed liver segment resection sucessfully after conversion therapy, and non‑tumor recurrence was observed at postoperative 9 months. Postoperative pathological examination showed combined hepatocellular‑cholangiocarcinoma, which also indicated the important value of T+A regimen in the conversion therapy of combined hepatocellular‑cholangiocarcinoma.